EP0641212A4 - Verfahren und wirkstoff zur hemmung der krebsentwicklung. - Google Patents

Verfahren und wirkstoff zur hemmung der krebsentwicklung.

Info

Publication number
EP0641212A4
EP0641212A4 EP93911311A EP93911311A EP0641212A4 EP 0641212 A4 EP0641212 A4 EP 0641212A4 EP 93911311 A EP93911311 A EP 93911311A EP 93911311 A EP93911311 A EP 93911311A EP 0641212 A4 EP0641212 A4 EP 0641212A4
Authority
EP
European Patent Office
Prior art keywords
reagent
cancer development
inhibiting cancer
inhibiting
development
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93911311A
Other languages
English (en)
French (fr)
Other versions
EP0641212A1 (de
Inventor
James D Thompson
Kenneth G Draper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirna Therapeutics Inc
Original Assignee
Ribozyme Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/936,110 external-priority patent/US5610052A/en
Priority claimed from US07/936,532 external-priority patent/US6492512B1/en
Priority claimed from US07/936,421 external-priority patent/US5750390A/en
Application filed by Ribozyme Pharmaceuticals Inc filed Critical Ribozyme Pharmaceuticals Inc
Publication of EP0641212A1 publication Critical patent/EP0641212A1/de
Publication of EP0641212A4 publication Critical patent/EP0641212A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/123—Hepatitis delta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP93911311A 1992-05-14 1993-05-13 Verfahren und wirkstoff zur hemmung der krebsentwicklung. Withdrawn EP0641212A4 (de)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US88282292A 1992-05-14 1992-05-14
US88288592A 1992-05-14 1992-05-14
US882885 1992-05-14
US882822 1992-05-14
US93653192A 1992-08-26 1992-08-26
US93642292A 1992-08-26 1992-08-26
US936532 1992-08-26
US936110 1992-08-26
US936531 1992-08-26
US07/936,110 US5610052A (en) 1992-08-26 1992-08-26 Enzymatic RNA with activity to ras
US936421 1992-08-26
US936422 1992-08-26
US07/936,532 US6492512B1 (en) 1992-08-26 1992-08-26 Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression
US07/936,421 US5750390A (en) 1992-08-26 1992-08-26 Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
US98713192A 1992-12-07 1992-12-07
US987131 1992-12-07
US612293A 1993-01-19 1993-01-19
US891093A 1993-01-19 1993-01-19
US8910 1993-01-19
US6122 1993-01-19
PCT/US1993/004573 WO1993023057A1 (en) 1992-05-14 1993-05-13 Method and reagent for inhibiting cancer development

Publications (2)

Publication Number Publication Date
EP0641212A1 EP0641212A1 (de) 1995-03-08
EP0641212A4 true EP0641212A4 (de) 1997-05-21

Family

ID=27580619

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93911311A Withdrawn EP0641212A4 (de) 1992-05-14 1993-05-13 Verfahren und wirkstoff zur hemmung der krebsentwicklung.

Country Status (5)

Country Link
EP (1) EP0641212A4 (de)
JP (1) JPH08502950A (de)
AU (1) AU687001B2 (de)
CA (1) CA2135499A1 (de)
WO (1) WO1993023057A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2135646A1 (en) * 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
EP0750503A4 (de) * 1994-03-07 1999-07-21 Immusol Inc Ribozymtherapie für restenose
US5834440A (en) * 1994-03-07 1998-11-10 Immusol Incorporated Ribozyme therapy for the inhibition of restenosis
US6103890A (en) * 1994-05-18 2000-08-15 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids that cleave C-fos
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5989908A (en) * 1994-09-12 1999-11-23 City Of Hope Modulation of drug and radiation resistant genes
WO1996018733A2 (en) * 1994-12-14 1996-06-20 Innovir Laboratories, Inc. Ribozyme-mediated inactivation of leukemia-associated rna
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
EP1408111B1 (de) 1995-10-26 2010-06-09 Sirna Therapeutics, Inc. Verfahren und Reagenz zur Behandlung von Krankheiten die von der Konzentration des Rezeptors für den Wachstumsfaktor der vaskulären Endothelzellen verursacht werden
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US20020081733A1 (en) * 1995-11-14 2002-06-27 Catherine M. Verfaillie Method to prepare drug-resistant, non-malignant hematopoietic cells
WO1997037013A1 (en) * 1996-04-02 1997-10-09 Commonwealth Scientific And Industrial Research Organisation Asymmetric hammerhead ribozymes
US6238917B1 (en) * 1996-04-02 2001-05-29 Commonwealth Scientific Industrial Research Organizaion Asymmetric hammerhead ribozymes
ES2221942T3 (es) * 1996-05-24 2005-01-16 Aventis Pharma Deutschland Gmbh Reactivo y metodo para inhibir la expresion de n-ras.
US7329741B2 (en) * 1996-06-05 2008-02-12 Chiron Corporation Polynucleotides that hybridize to DP-75 and their use
US5807743A (en) * 1996-12-03 1998-09-15 Ribozyme Pharmaceuticals, Inc. Interleukin-2 receptor gamma-chain ribozymes
US6057156A (en) 1997-01-31 2000-05-02 Robozyme Pharmaceuticals, Inc. Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
US6482932B1 (en) 1997-11-05 2002-11-19 Ribozyme Pharmaceuticals, Incorporated Nucleoside triphosphates and their incorporation into oligonucleotides
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6127535A (en) 1997-11-05 2000-10-03 Ribozyme Pharmaceuticals, Inc. Nucleoside triphosphates and their incorporation into oligonucleotides
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US6875747B1 (en) * 1999-05-24 2005-04-05 Avi Bio Pharma, Inc. Antisense to c-myc for treatment of polycystic kidney disease
US6607915B1 (en) * 1999-09-30 2003-08-19 Isis Pharmaceuticals, Inc. Antisense inhibition of E2A-Pbx1 expression
US6682902B2 (en) 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US7754435B2 (en) 2000-09-21 2010-07-13 Philadelphia Health And Education Corporation Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
JP3910536B2 (ja) * 2000-12-28 2007-04-25 塩野義製薬株式会社 新規ポリペプチドおよびそのｄｎａ
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
EP1375661A1 (de) * 2002-06-17 2004-01-02 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Die Rolle der N-myc - nm23H1/nm23H2 - cdc42 Kaskade in der Proliferation, der Differenzierung und der Behandlung von Krebs
CA2489726A1 (en) * 2002-06-18 2003-12-24 Irm Llc Diagnosis and treatment of chemoresistant tumors
WO2004105774A1 (ja) * 2003-05-30 2004-12-09 Nippon Shinyaku Co., Ltd. オリゴ核酸担持複合体、当該複合体を含有する医薬組成物
EP2756845B1 (de) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Verfahren und Zusammensetzungen für spezifische KRAS-Hemmung mit asymmetrischer Doppelstrang-RNA
CN103555722B (zh) 2009-04-03 2016-08-31 戴瑟纳制药公司 利用不对称双链rna特异性抑制kras的方法和组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0387775A1 (de) * 1989-03-16 1990-09-19 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Genetische Einheiten zur Inhibierung der Funktion von RNA
WO1991004324A1 (en) * 1989-09-25 1991-04-04 Innovir Laboratories, Inc. Ribozyme compositions and methods for use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018913A1 (en) * 1990-06-07 1991-12-12 City Of Hope Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
AU7152191A (en) * 1990-06-07 1991-12-31 City Of Hope Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
WO1992000080A1 (en) * 1990-06-26 1992-01-09 The Wistar Institute Of Anatomy & Biology Method for treating leukemias

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0387775A1 (de) * 1989-03-16 1990-09-19 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Genetische Einheiten zur Inhibierung der Funktion von RNA
WO1991004324A1 (en) * 1989-09-25 1991-04-04 Innovir Laboratories, Inc. Ribozyme compositions and methods for use

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
83RD ANN. MEET. AM. ASSOC. CANCER RES., MAY 20-23, 1992 , SAN DIEGO, CA *
CHANG, E. & MILLER, P.: "Ras, an inner membrane transducer of growth stimuli", WICKSTROM, E. 'PROSPECTS FOR ANTISENSE NUCLEIC ACID THERAPY OF CANCER AND AIDS'; WILEY-LISS; 1991, pages 115 - 124, XP002027819 *
HOLM, P. ET AL.: "CONSTRUCTION OF A RIBOZYME WITH CATALYTIC ACTIVITY AGAINST THE MRNA OF THE MULTIDRUG RESISTANCE-ASSOCIATED P-GLYCOPROTEIN .", PROC ANNU MEET AM ASSOC CANCER RES, (1992). VOL. 33, PP. 401. ABSTRACT 2393., XP000647577 *
KASHANI-SABET M ET AL: "REVERSAL OF THE MALIGNANT PHENOTYPE BY AN ANTI-RAS RIBOZYME", ANTISENSE RESEARCH AND DEVELOPMENT, vol. 2, no. 1, 1992, pages 3 - 15, XP000576012 *
KOBAYASHI H ET AL: "Cleavage of human MDR1 mRNA by a hammerhead ribozyme.", FEBS LETTERS, (1993 MAR 15) 319 (1-2) 71-4., XP002027820 *
See also references of WO9323057A1 *
STEPHENSON P ET AL: "IN VITRO CLEAVAGE OF AN N-RAS MESSENGER-LIKE RNA BY A RIBOZYME", ANTISENSE RESEARCH AND DEVELOPMENT, vol. 1, 1991, pages 261 - 268, XP000196553 *

Also Published As

Publication number Publication date
AU687001B2 (en) 1998-02-19
AU4248993A (en) 1993-12-13
CA2135499A1 (en) 1993-11-25
JPH08502950A (ja) 1996-04-02
EP0641212A1 (de) 1995-03-08
WO1993023057A1 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
EP0641212A4 (de) Verfahren und wirkstoff zur hemmung der krebsentwicklung.
EP0642589A4 (de) Methode und reagenz zur inhibierung der viralen replikation.
EP0586125A3 (de) Verfahren und Testsatz zum Nachweis von Sprengstoffen.
GB9612528D0 (en) Method for diagnosing cancer
HK1009440A1 (en) Benzopyran-containing compounds and method for their use.
GB2298613B (en) Dual card and method therefor
EP0655625A3 (de) Sensorelemente und Verfahren zu ihrer Herstellung.
EP0587162A3 (de) Datenverarbeitungsgerät.
EP0592808A3 (de) Geschäftliche Datenmaskierung.
IL114188A0 (en) Method for idal-in access security
EP0601848A3 (en) System and method for knowledge based design.
EP0585944A3 (de) Informationsverarbeitungsverfahren und -vorrichtung.
EP0645630A3 (de) Verfahren zur Bestimmung der Anwesenheit eines Pivkas und Reagens dazu.
EP0584828A3 (de) Automatisiertes LSI-Entwurfsystem.
EP0605108A3 (en) Development processes.
GB9214514D0 (en) Information processing
EP0584776A3 (de) Datenverarbeitungsverfahren und -gerät.
GB2298502B (en) Data processing method
GB2284054B (en) Method for range determination
ZA93782B (en) Determination method.
GB2266167B (en) Communicating system and method for communicating data
ZA932652B (en) Method for the elimination of non-specific reactions in immunoassays.
HUP9904330A3 (en) Perfluoroalkylation method and reagent therefor
EP0578138A3 (de) Verfahren zum Gennachweis.
ZA931558B (en) Anti-tumor method and anti-tumor agent.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/52

A4 Supplementary search report drawn up and despatched

Effective date: 19970407

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000517

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041201